Synergism between clofarabine and decitabine through p53R2: A pharmacodynamic drug-drug interaction modeling

Leukemia Research

Volumn 36, Issue 11, 2012, Pages 1410-1416

  Thudium, Karen E ^a,b,d   Ghoshal, Sampa ^a,e   Fetterly, Gerald J ^a,b   Haese, Jason P Den ^a,c   Karpf, Adam R ^a,f   Wetzler, Meir ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c D'YOUVILLE COLLEGE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

AML; Clofarabine; Decitabine; Pharmacodynamic modeling; Synergy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CLOFARABINE; PROTEIN P53; SHORT HAIRPIN RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG POTENTIATION; HILL REACTION; HUMAN; HUMAN CELL; INCUBATION TIME; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT OUTCOME; UPREGULATION;

ADENINE NUCLEOTIDES; ARABINONUCLEOSIDES; AZACITIDINE; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; HUMANS; PROTEIN BIOSYNTHESIS; RIBONUCLEOTIDE REDUCTASES;

EID: 84866316783     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.07.015     Document Type: Article

References (16)

1. Burnett A., Wetzler M., Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011, 29:487-494.
2. Pui C.H., Jeha S., Clofarabine Nat Rev Drug Discov 2005, (suppl.):S12-S13.
3. Montgomery J.A., Shortnacy-Fowler A.T., Clayton S.D., Riordan J.M., Secrist J.A. Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-d-arabinofuranosyladenine. J Med Chem 1992, 35:397-401.
4. Kantarjian H.M., Erba H.P., Claxton D., Arellano M., Lyons R.M., Kovascovics T., et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010, 28:549-555.
5. Burnett A.K., Russell N.H., Kell J., Dennis M., Milligan D., Paolini S., et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010, 28:2389-2395.
6. Gandhi V., Kantarjian H., Faderl S., Bonate P., Du M., Ayres M., et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 2003, 9:6335-6342.
7. Mansson E., Flordal E., Liliemark J., Spasokoukotskaja T., Elford H., Lagercrantz S., et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol 2003, 65:237-247.
8. Blum W., Garzon R., Klisovic R.B., Schwind S., Walker A., Geyer S., et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010, 107:7473-7478.
9. Link P.A., Baer M.R., James S.R., Jones D.A., Karpf A.R. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res 2008, 68:9358-9366.
10. Cashen A.F., Shah A.K., Todt L., Fisher N., DiPersio J. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 2008, 61:759-766.
11. Wetzler M., Earp J.C., Brady M.T., Keng M.K., Jusko W.J. Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity - pharmacodynamic drug-drug interaction modeling. Clin Cancer Res 2007, 13:2261-2270.
12. Benekli M., Xia Z., Donohue K.A., Ford L.A., Pixley L.A., Baer M.R., et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 2002, 99:252-257.
13. D'Argenio D., Schumitzky A., Wang X. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic system analysis software 2009, Biomedical Simulations Resource, Los Angeles.
14. Ariens E.J., Simonis A.M. A molecular basis for drug action. J Pharm Pharmacol 1964, 16:137-157.
15. Chakraborty A., Jusko W.J. Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation. J Pharm Sci 2002, 91:1334-1342.
16. Ghoshal S., Rao I., Earp J.C., Jusko W.J., Wetzler M. Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. Cancer Chemother Pharmacol 2010, 66:681-689.